Pfizer Inc. (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
Pfizer announces positive top-line results from Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants
August 18, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022